Literature DB >> 17391162

IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients.

M Monami1, N Marchionni, G Masotti, E Mannucci.   

Abstract

AIM: The metabolic syndrome (MS) is associated with increased cardiovascular morbidity and mortality. Recently, the International Diabetes Federation (IDF) proposed to lower diagnostic thresholds for fasting glucose and waist circumference and to limit the diagnosis of MS only to subjects with abdominal adiposity. The aim of the present study was to assess the prognostic value of IDF criteria in diabetic patients, in comparison with previous ATP-III criteria.
METHODS: An observational cohort study was performed on a consecutive series of 882 Caucasian type 2 diabetic outpatients, aged 65.3 +/- 10.9 years, with a duration of diabetes of 13.1 +/- 10.6 years. Information on 3-year all-cause mortality was obtained by the City of Florence Registry Office.
RESULTS: The prevalence of MS was 68.4 and 73.7% using ATP-III and IDF criteria, respectively. Over the follow-up period, 115 (13.6%) deaths were recorded. Patients with ATP-III-defined MS showed a significantly higher mortality rate when compared with the rest of the sample (16.1% vs. 8.2%; p = 0.002), whereas a non-significant trend was observed using IDF classification (14.9% vs. 10.0%, p = 0.064). At Cox regression analysis, after adjustment for sex, age, and its individual components, diagnosis of MS with ATP-III criteria, but not with IDF criteria [OR (95% CI) 1.65 (0.99-2.72), p = 0.053], was significantly associated with higher mortality [OR (95%,CI) 2.38 [1.18-4.76]).
CONCLUSION: In conclusion, in Caucasian type 2 diabetic patients the application of IDF criteria determines an increase of estimated prevalence of MS, without improving its prognostic value. Further studies are needed before the newer IDF criteria for MS are adopted on a larger scale.

Entities:  

Mesh:

Year:  2007        PMID: 17391162     DOI: 10.1111/j.1463-1326.2006.00615.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  15 in total

Review 1.  Hypogonadism and metabolic syndrome.

Authors:  G Corona; G Rastrelli; A Morelli; L Vignozzi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-06-27       Impact factor: 4.256

2.  Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Authors:  Todd M Brown; Jenifer H Voeks; Vera Bittner; Monika M Safford
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

Review 3.  Dialysis-treated end-stage kidney disease in Libya: epidemiology and risk factors.

Authors:  Fathea Abobker Goleg; Norella Chiew-Tong Kong; Ramesh Sahathevan
Journal:  Int Urol Nephrol       Date:  2014-03-27       Impact factor: 2.370

4.  The relation of metabolic syndrome according to five definitions to cardiovascular risk factors--a population-based study.

Authors:  Cheng-Chieh Lin; Chiu-Shong Liu; Chia-Ing Li; Wen-Yuan Lin; Ming-May Lai; Tsann Lin; Pei-Chia Chang; Yih-Dar Lee; Ching-Chu Chen; Chih-Hsueh Lin; Chuan-Wei Yang; Chih-Yi Hsiao; Walter Chen; Tsai-Chung Li
Journal:  BMC Public Health       Date:  2009-12-23       Impact factor: 3.295

5.  Prognostic value of International Diabetes Federation and Adult Treatment Panel III definitions of metabolic syndrome in Type 2 diabetic patients: what makes the difference?

Authors:  M Monami; N Marchionni; G Masotti; E Mannucci
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

Review 6.  Perturbed autonomic nervous system function in metabolic syndrome.

Authors:  Nicholas Tentolouris; Georgia Argyrakopoulou; Nicholas Katsilambros
Journal:  Neuromolecular Med       Date:  2008-01-26       Impact factor: 3.843

7.  Metabolic syndrome in type 2 diabetes: comparative prevalence according to two sets of diagnostic criteria in sub-Saharan Africans.

Authors:  Andre P Kengne; Serge N Limen; Eugene Sobngwi; Cathérine Ft Djouogo; Christophe Nouedoui
Journal:  Diabetol Metab Syndr       Date:  2012-05-31       Impact factor: 3.320

8.  Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi-Libya: A pilot study.

Authors:  Mm Alshkri; Rr Elmehdawi
Journal:  Libyan J Med       Date:  2008-12-01       Impact factor: 1.657

9.  Risk Factors for Cardiovascular Diseases among Diabetic Patients In Southwest Ethiopia.

Authors:  Solomon Tamiru; Fessahaye Alemseged
Journal:  Ethiop J Health Sci       Date:  2010-07

Review 10.  The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.

Authors:  Rebecca Hutcheson; Petra Rocic
Journal:  Exp Diabetes Res       Date:  2012-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.